Phenotypic Discovery of SB1501, an Anti-obesity Agent, through Modulating Mitochondrial Activity

Area of Science:

• Biochemistry
• Metabolic Disorders
• Pharmacology

Background:

• Obesity is a global pandemic requiring new therapeutic strategies.
• Obesity is linked to detrimental metabolic disorders.
• Novel anti-obesity agents are crucial for improving public health.

Purpose of the Study:

• To identify novel anti-obesity agents using a phenotype-based screening approach.
• To evaluate the efficacy of a newly identified compound, SB1501, in preclinical models of obesity.

Main Methods:

• Utilized image-based high-content screening with a lipid droplet-visualizing bioprobe (SF44).
• Conducted structure-activity relationship studies to optimize lead compounds.
• Assessed compound effects on 3T3-L1 adipocytes and in diet-induced obesity mouse models (db/db mice).
• Analyzed gene expression related to mitochondrial biogenesis and fatty acid oxidation.

Main Results:

• Identified SB1501 as a non-cytotoxic compound that reduces lipid droplets in adipocytes.
• SB1501 treatment increased mitochondrial biogenesis and fatty acid oxidation gene expression.
• SB1501 treatment in db/db mice reduced body fat, adipose tissue mass, and food intake, while improving glucose tolerance.
• Observed modulation of the PGC-1α-UCP1 axis in adipose tissues.

Conclusions:

• SB1501 demonstrates significant anti-obesity effects in vitro and in vivo.
• The mechanism involves enhanced mitochondrial activity and perturbation of the PGC-1α-UCP1 pathway.
• SB1501 holds therapeutic potential for combating obesity and associated metabolic dysfunctions.